fluoxetine has been researched along with nifedipine in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 12 (35.29) | 29.6817 |
| 2010's | 20 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YS; Hwang, EM; Jung, SY; Lim, SM; Min, SJ; Pae, AN; Park, KD; Viswanath, AN | 1 |
| Bauer, C; Caldwell, L; Kinnier, WJ; Lancaster, J; McMillan, B; Price, CH; Sweetnam, PM | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Jia, L; Sun, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Azaz-Livshits, TL; Danenberg, HD | 1 |
| Ballester, R; Chuan, P; Domenech, C; Lluch, S; Medina, P; Segarra, G; Vila, JM | 1 |
| Koller, A; Pacher, P; Ungvari, Z | 1 |
| Black, CM; Blann, A; Coleiro, B; Denton, CP; Howell, K; Marshall, SE; Welsh, KI | 1 |
| Ghafourifar, P; Mousavizadeh, K; Sadeghi-Nejad, H | 1 |
| Liang, JH; Liu, RK; Sun, HL; Wang, XH; Ye, XF; Zheng, JW | 1 |
| Chen, B; Han, R; Li, JX; Liang, JH; Lu, Y; Wang, XH; Ye, XF; Zhang, P | 1 |
| Bi, XP; Cai, XJ; Wang, L; Zhao, Z | 1 |
| Capuano, V; Ferron, L; Renaud, JF; Ruchon, Y; Sankhe, S | 1 |
| Du, T; Hertz, L; Li, B; Liang, C; Peng, L | 1 |
| Eren Cevik, S; Guneysel, O; Tasyurek, T | 1 |
3 review(s) available for fluoxetine and nifedipine
| Article | Year |
|---|---|
The role of receptor binding in drug discovery.
Topics: Animals; Drug Design; Humans; Receptors, Drug | 1993 |
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for fluoxetine and nifedipine
| Article | Year |
|---|---|
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adult; Aged; Cold Temperature; Cross-Over Studies; Female; Fluoxetine; Humans; Male; Middle Aged; Nifedipine; Prospective Studies; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Self-Examination; Severity of Illness Index; Thermography; Treatment Outcome; von Willebrand Factor | 2001 |
[The effects of antidepressant treatment on efficacy of antihypertensive therapy in elderly hypertension].
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Depressive Disorder; Female; Fluoxetine; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Nifedipine; Treatment Outcome | 2006 |
29 other study(ies) available for fluoxetine and nifedipine
| Article | Year |
|---|---|
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
Topics: Animals; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Mice; Mice, Knockout; Molecular Docking Simulation; Potassium Channels, Tandem Pore Domain | 2016 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Drug Interactions; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Hypertension; Hypotension, Orthostatic; Nifedipine; Selective Serotonin Reuptake Inhibitors; Tachycardia | 1997 |
Effects of antidepressants in adrenergic neurotransmission of human vas deferens.
Topics: Amitriptyline; Antidepressive Agents; Calcium; Calcium Channel Blockers; Culture Techniques; Dose-Response Relationship, Drug; Fluoxetine; Humans; Male; Muscle Contraction; Nifedipine; Receptors, Adrenergic; Sertraline; Synaptic Transmission; Vas Deferens | 2000 |
Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Arterioles; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Dose-Response Relationship, Drug; Fluoxetine; In Vitro Techniques; Male; Muscle Tonus; Muscle, Skeletal; Muscle, Smooth, Vascular; Nifedipine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2000 |
Calcium channel blocking activity of thioridazine, clomipramine and fluoxetine in isolated rat vas deferens: a relative potency measurement study.
Topics: Animals; Antidepressive Agents; Calcium; Calcium Channel Blockers; Clomipramine; Dose-Response Relationship, Drug; Fluoxetine; In Vitro Techniques; Male; Muscle Contraction; Nifedipine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Thioridazine; Vas Deferens | 2002 |
Buspirone-induced antinociception is mediated by L-type calcium channels and calcium/caffeine-sensitive pools in mice.
Topics: 5-Hydroxytryptophan; Analgesics; Animals; Buspirone; Caffeine; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Chloride; Central Nervous System Stimulants; Chelating Agents; Egtazic Acid; Female; Fluoxetine; Injections, Intraventricular; Mice; Nifedipine; Pain Measurement; Reaction Time; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Ryanodine; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2003 |
L-type calcium channel blockers enhance 5-HTP-induced antinociception in mice.
Topics: 5-Hydroxytryptophan; Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Chloride; Chelating Agents; Drug Synergism; Egtazic Acid; Female; Fluoxetine; Injections, Intraventricular; Mice; Motor Activity; Nifedipine; Nimodipine; Pain Measurement; Pargyline; Selective Serotonin Reuptake Inhibitors; Verapamil | 2004 |
T-type Ca²⁺ signalling downregulates MEK1/2 phosphorylation and cross-talk with the RAAS transcriptional response in cardiac myocytes.
Topics: Animals; Calcium Signaling; Flunarizine; Fluoxetine; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mibefradil; Mifepristone; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Nifedipine; Phosphorylation; Rats; Rats, Wistar; Receptors, Glucocorticoid; Renin-Angiotensin System; Spironolactone | 2012 |
Chronic fluoxetine administration increases expression of the L-channel gene Cav1.2 in astrocytes from the brain of treated mice and in culture and augments K(+)-induced increase in [Ca(2+)]i.
Topics: Animals; Astrocytes; Brain; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cells, Cultured; Female; Fluoxetine; Ions; Male; Mice; Mice, Transgenic; Nifedipine; Potassium Chloride; RNA Interference; RNA, Small Interfering; Ryanodine; Up-Regulation | 2014 |
Intralipid emulsion treatment as an antidote in lipophilic drug intoxications.
Topics: Adolescent; Adult; Alprazolam; Amitriptyline; Antidotes; Blood Pressure; Dibenzothiazepines; Drug Overdose; Fat Emulsions, Intravenous; Female; Fluoxetine; Glasgow Coma Scale; Heart Rate; Humans; Lamotrigine; Lipid Metabolism; Male; Metoprolol; Middle Aged; Nifedipine; Quetiapine Fumarate; Triazines; Young Adult | 2014 |